These Obesity Stocks Are Just Starting to Rebound
The global obesity epidemic has become one of the defining healthcare challenges of our time. According to the World Health Organization, more than 1 billion people worldwide are now obese — a number expected to continue climbing. That has created a massive and fast-growing market for pharmaceutical companies developing effective treatments, particularly GLP-1-based therapies, which have shown promise in promoting weight loss.
While big players like Novo Nordisk and Eli Lilly have grabbed headlines with blockbuster obesity drugs like Wegovy and Zepbound, several smaller biotech stocks are flying under the radar — and may be poised for substantial upside as they advance in clinical trials.
After a broad pullback in the biotech sector, many of these names are trading at deeply discounted levels. But recent developments in the obesity treatment space suggest a rebound may be underway. Here are three of the most promising plays in this sector –
| Company: Viking Therapeutics (SYM: VKTX) Viking Therapeutics is emerging as one of the most compelling small-cap names in the obesity space. The company is developing VK2735, a dual GLP-1/GIP receptor agonist for the treatment of obesity and related metabolic disorders. The injectable version of VK2735 has already delivered promising data. In Phase 2 trials, patients saw meaningful weight loss over a relatively short treatment window. Now, Viking is preparing to enter Phase 3 trials — a major catalyst that could significantly re-rate the stock. In a recent press release, CEO Brian Lian confirmed the company is on track: “We are advancing this compound into Phase 3 development,” he said, adding that Viking expects to meet with regulators later this year to finalize the trial design. That’s not all. Viking is also developing an oral version of VK2735, which has shown positive results in Phase 1. The oral candidate demonstrated encouraging safety and tolerability, along with weight loss of up to 5.3% after just 28 days. The company plans to initiate Phase 2 trials for the oral formulation later this year. Oral GLP-1 therapies represent one of the most exciting frontiers in obesity treatment, as they remove the barrier of injections — potentially expanding the addressable market dramatically. Given that VKTX traded as high as $90 in early 2024, today’s price near $28 could represent a significant discount if the company continues to hit its milestones. |
Crypto 101
Breaking: Trump’s Crypto Revolution Triggers Financial Boom
Trump’s pro-crypto agenda is sending markets surging as tariff concerns evaporate – and one token stands to benefit more than any other. This infrastructure powerhouse sits at the absolute center of Trump’s crypto vision, yet amazingly remains available at bargain prices… for now.
Just Released: The #1 crypto set to explode from Trump’s policies –
| Company: Structure Therapeutics (SYM: GPCR) Structure Therapeutics is another under-the-radar name that may soon attract much more investor attention. The company is focused on developing GSBR-1290, an oral GLP-1 receptor agonist for obesity and type 2 diabetes. In April, Structure reported topline data from its Phase 2a obesity study of GSBR-1290. The results were strong: patients receiving the drug saw a statistically significant placebo-adjusted mean weight loss of 6.2% at 12 weeks — a compelling result for an oral therapy at this stage. GPCR is now preparing for a more extensive 36-week Phase 2b study, expected to launch in the fourth quarter of 2025. If results remain favorable, this could dramatically increase investor interest and position the company as a serious contender in the obesity treatment space. What makes GPCR particularly interesting is its “pure play” status in the oral GLP-1 market. Unlike larger pharmaceutical companies with diversified portfolios, Structure Therapeutics offers a focused bet on a single, high-growth segment. As JPMorgan analysts recently noted: “We think the opportunity for oral GLP-1s is underappreciated and think this market could generate $30 billion in sales by 2035.” Even a small share of that market could mean explosive upside for GPCR, whose market cap is still relatively modest. |
Mode Mobile
Apple stumbles while these guys just paid out $325M
Mode Mobile’s 32,481% revenue growth over a 3 year period proves it.
Mode has secured their Nasdaq ticker ($MODE) ahead of a potential public offering, and pre-IPO shares are available at just $0.30.
Plus…
Early investors are receiving up to 100% BONUS shares.
The moment in time when industry leaders get comfortable and miss what consumers really want…
That’s when disruptors emerge.
Apple did it to BlackBerry, and now Mode is positioned to do it to Apple.
And you can be a part of it for just $0.30/share.
Hurry– invest in Mode at $0.30/share while you still can.
| Company: Altimmune (SYM: ALT) After plunging from about $6 to a low of about $3.55, ALT is just starting to rebound. Last trading at $5.80, we’d like to see it challenge $7.50 again near term. Helping, the company recently submitted Investigational New Drug (IND) applications for pemvidutide in two additional indications at the end of 2024, both of which have been cleared by FDA. We should also note that Altimmune recently released Phase 2 data on pemvidutide, which showed that study participants lost a mean of 15.6% of body weight at 48 weeks based on the highest dose tested. Reportedly, the treatment also led to “better lean mass preservation compared to other marketed incretin mimetic medications, such as Novo Nordisk’s Wegovy (semaglutide) and Eli Lilly’s (Zepbound (tirzepatide).” After all, preservation of lean mass with weight loss is critical, says the company. If a person loses too much lean mass during weight loss, it can lead to severe medical outcomes, such as musculoskeletal issues and bone fractures. Also, if ALT can show further success in safely treating obesity, it could open a massive $130 billion global obesity market opportunity for the $489 million company. As noted by Goldman Sachs, the global obesity treatment market could grow to $130 billion by 2030. Even Morgan Stanley expects the global obesity drug treatment market to reach $105 billion by 2030 from $77 billion. At the high end, $144 billion. |
Stansberry Research
Bloomberg: “[This] could achieve a $40 trillion valuation”
If you missed out on Amazon, Netflix, Apple…
Stay tuned, because Bloomberg says Jeff Bezos’ new project could “achieve a $40 trillion valuation.”
If you play this right, you could capture huge profits.
But according to Whitney Tilson, the former hedge fund manager who bought Amazon before it soared more than 8,000%, Netflix before it soared more than 11,000%, and Apple before the stock soared more than 65,000%…
You have to move quickly.
